ViiV Healthcare – MPP – Aurobindo

In 2019, ViiV Healthcare, the Medicines Patent Pool (MPP) and Aurobindo signed a memorandum of understanding (MoU) agreeing to exchange information and business leads to fast-track the development and uptake of the antiretroviral dolutegravir (DTG). MPP signed licences with ViiV Healthcare on DTG for adult and paediatric care and signed sublicences with 13 generic manufacturers to produce DTG and DTG containing formulations for low- and middle-income countries.

Aurobindo has a bilateral agreement for DTG with ViiV Healthcare, and since the signature of a Memorandum of Understanding with MPP in 2018, Aurobindo has regularly shared data on the development and uptake of DTG with MPP. Under the terms of the collaborative agreement signed by the three parties in 2019, a sub-set of Aurobindo’s data is shared by MPP with ViiV Healthcare. Such sub-set data is valuable for ViiV Healthcare in order to assess the overall impact on access to DTG made by all generic manufacturers (MPP licensees and Aurobindo).